In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Mechanical dispersion by speckle tracking imaging in Brugada syndrome patients

Session Clinical impact of strain imaging

Speaker Esther Scheirlynck

Event : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Tissue Doppler, Speckle Tracking and Strain Imaging
  • Session type : Abstract Session

Authors : E Scheirlynck (Brussels,BE), S Van Malderen (Sint-Niklaas,BE), A Motoc (Brussels,BE), J Sieira (Brussels,BE), C De Asmundis (Brussels,BE), GB Chierchia (Brussels,BE), P Brugada (Brussels,BE), S Droogmans (Brussels,BE), B Cosyns (Brussels,BE)

Authors:
E. Scheirlynck1 , S. Van Malderen2 , A. Motoc1 , J. Sieira1 , C. De Asmundis1 , G.B. Chierchia1 , P. Brugada1 , S. Droogmans1 , B. Cosyns1 , 1University Hospital (UZ) Brussels, Centrum voor Hart- en Vaatziekten - Brussels - Belgium , 2AZ Nikolaas, Cardiology Department - Sint-Niklaas - Belgium ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1043-1044

Background: Brugada syndrome (BrS) is associated with an increased risk for severe ventricular arrhythmias and sudden cardiac death. Although labeled as a disease occurring in structurally normal hearts, functional alterations in some patients, mostly affecting the right ventricle (RV) and less often the left ventricle (LV), have been identified using new imaging techniques. Mechanical dispersion (MD) by speckle tracking imaging has been previously used to predict arrhythmic events in various cardiomyopathies.

Purpose: To evaluate if LV and RV global longitudinal strain (GLS) and MD by speckle tracking analysis differ between BrS patients and healthy matched controls.

Methods: We included 148 patients with BrS and 67 healthy controls. Patients with coronary heart disease were excluded. For each patient, speckle tracking analysis was performed in 16 LV and 6 RV segments. The time to peak myocardial strain in each segment was measured as the time from onset of the QRS complex on the ECG to maximum myocardial shortening. GLS was defined as the mean of the peak strain in the 16 LV segments and the 3 RV free wall segments. MD was defined as the standard deviation of the time to peak in respectively the 16 LV segments, the 6 RV segments and the 3 RV free wall segments.

Results: LV, RV and RV free wall MD were significantly higher in patients with BrS than in healthy controls [38 (±11) vs. 33 (±8) ms, P<0.001; 29 (±17) vs. 24 (±14) ms, P<0.05; 20 (±17) vs. 15 (±11) ms, P=0.004]. LV and RV GLS did not differ significantly between BrS patients and healthy controls [-18.7 (±2.3) vs. -19.0 (±1.9) %, P=0.39 and -25.9 (±5.2) vs. -25.8 (±3.5) %, P=0.90].

Conclusion: BrS patients had a higher MD than healthy controls, both in the LV and RV. Both LV and RV GLS were not significantly altered in BrS compared to healthy controls. Therefore, MD by speckle tracking might be a potential marker for the risk stratification of arrhythmic events in BrS.

Demographics and Speckle tracking data
All (215)BrS (148)Controls (67)p-value
Age (y)45±1445±1445±130.724
Female n (%)108 (50)73 (49)35 (51)0.884
GLS LV (%)-18.8±2.2-18.7±2.3-19.0±1.90.392
MD LV (ms)36±1138±1133±8<0.001
GLS RV (%)-25.8±4.7-25.9±5.2-25.8±3.50.896
MD RV (ms)27±1629±1724±140.046
MD RV free wall (ms)19±1620±1715±110.004
BrS = Brugada syndrome, GLS = global longitudinal strain, LV = left ventricle, MD = mechanical dispersion, RV = right ventricle.
LV mechanical dispersion

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are